Adhera Therapeutics Inc. (ATRX) 股价，以美元计价

Marina Biotech, Inc. is a fully integrated, commercial stage pharmaceutical company delivering proprietary drug therapeutics for significant unmet medical needs in the U.S., Europe and certain additional international markets. Our portfolio of products focuses on fixed dose combinations ("FDCs") in hypertension, arthritis, pain and oncology allowing for innovative solutions to such unmet medical needs. Our mission is to provide effective and patient centric treatment for hypertension - including resistant hypertension. We currently have one commercial and three clinical development programs underway: (i) Prestalia, a single-pill FDC of perindopril and amlodipine, which has been approved by the FDA and is actively marketed in the U.S.; (ii) our next generation celecoxib program drug candidates for the treatment of acute and chronic pain, IT-102 and IT-103, each of which is an FDC of celecoxib and either lisinopril (IT-102) or olmesartan (IT-103); (iii) CEQ508, an oral delivery of small interfering RNA against beta-catenin, combined with IT-102 to suppress polyps in the precancerous syndrome and orphan indication Familial Adenomatous Polyposis; and (iv) CEQ508 combined with IT-103 to treat Colorectal Cancer.